Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Hypersensitivity Reaction

Free Subscription Articles published in Lancet Retrieve available abstracts of 42 articles: HTML format

Single Articles

February 2024
1. ROSAS-SALAZAR C, Gebretsadik T, Dupont WD, Hartert TV, et al
   The INSPIRE study: RSV infection during infancy - Authors' reply.
   Lancet. 2024;403:729-730.
   PubMed    
   
   
   January 2024
2. QUINT JK, Shah PL
   What trials do and do not tell us about treatments for severe asthma.
   Lancet. 2024;403:224-226.
   PubMed    
   
   
   
3. MAURER M, Ensina LF, Gimenez-Arnau AM, Sussman G, et al
   Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
   Lancet. 2024;403:147-159.
   PubMed     Abstract available
   
   
   
4. MOUSSA S, Netchiporouk E
   Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria.
   Lancet. 2024;403:118-119.
   PubMed    
   
   
   December 2023
5. DRUCKER NA, Cox CS Jr
   Adult presentation of congenital tracheooesophageal fistula treated as asthma and recurrent respiratory infections.
   Lancet. 2023;402:2326-2327.
   PubMed    
   
   
   
6. JACKSON DJ, Heaney LG, Humbert M, Kent BD, et al
   Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.
   Lancet. 2023 Dec 7:S0140-6736(23)02284-5. doi: 10.1016/S0140-6736(23)02284.
   PubMed     Abstract available
   
   
   November 2023
7. GUTTMAN-YASSKY E, Simpson EL, Reich K, Kabashima K, et al
   Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply.
   Lancet. 2023;402:1834.
   PubMed    
   
   
   
8. DEVJANI S, Engel PV, Javadi SS, Smith B, et al
   Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis.
   Lancet. 2023;402:1833-1834.
   PubMed    
   
   
   
9. GEDEON E, Henderson M, Leyland AH, Allik M, et al
   Association between care experience and mental health hospitalisation among children in Scotland, with a focus on chronic conditions (CHiCS): a population-wide longitudinal study using administrative data.
   Lancet. 2023;402 Suppl 1:S5.
   PubMed     Abstract available
   
   
   
10. ALYAMI RA, Simpson R, Oliver P, Julious SA, et al
    Evaluation of the impact of letters to GP practices to promote asthma prescription uptake in school-age children during summer (TRAINS study): a pragmatic cluster-randomised controlled trial.
    Lancet. 2023;402 Suppl 1:S22.
    PubMed     Abstract available
    
    
    September 2023
11. HANOUNEH M, Arend LJ
    Ichthyosis in sarcoidosis: a rare skin manifestation of a systemic disease.
    Lancet. 2023;402:1083-1084.
    PubMed    
    
    
    July 2023
12. LEVY ML, Bateman ED, Allan K, Bacharier LB, et al
    Global access and patient safety in the transition to environmentally friendly respiratory inhalers: the Global Initiative for Asthma perspective.
    Lancet. 2023 Jul 19:S0140-6736(23)01358-2. doi: 10.1016/S0140-6736(23)01358.
    PubMed    
    
    
    June 2023
13. PETRUSHKIN H, Solebo AL
    Imaging inflammation in early-onset sarcoidosis: granulomatous anterior uveitis in a 7-year-old girl.
    Lancet. 2023;401:1963.
    PubMed    
    
    
    April 2023
14. BILLARD MN, Bont LJ
    The link between respiratory syncytial virus infection during infancy and asthma during childhood.
    Lancet. 2023 Apr 19:S0140-6736(23)00672-4. doi: 10.1016/S0140-6736(23)00672.
    PubMed    
    
    
    
15. ROSAS-SALAZAR C, Chirkova T, Gebretsadik T, Chappell JD, et al
    Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study.
    Lancet. 2023 Apr 19:S0140-6736(23)00811-5. doi: 10.1016/S0140-6736(23)00811.
    PubMed     Abstract available
    
    
    
16. JAVAUD N, Gobert D
    Hereditary angioedema: is there a better future for treatment?
    Lancet. 2023;401:1054-1055.
    PubMed    
    
    
    
17. CRAIG TJ, Reshef A, Li HH, Jacobs JS, et al
    Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023;401:1079-1090.
    PubMed     Abstract available
    
    
    February 2023
18. AYGOREN-PURSUN E, Zanichelli A, Cohn DM, Cancian M, et al
    An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
    Lancet. 2023;401:458-469.
    PubMed     Abstract available
    
    
    
19. RESHEF A, Grumach AS
    New medications to mitigate attacks of hereditary angioedema: does one size fit all?
    Lancet. 2023;401:413-415.
    PubMed    
    
    
    January 2023
20. PORSBJERG C, Melen E, Lehtimaki L, Shaw D, et al
    Asthma.
    Lancet. 2023 Jan 19:S0140-6736(22)02125-0. doi: 10.1016/S0140-6736(22)02125.
    PubMed     Abstract available
    
    
    December 2022
21. THYSSEN JP, Schmid-Grendelmeier P
    Long-term disease control in atopic dermatitis using biologics.
    Lancet. 2022 Dec 9:S0140-6736(22)02347-9. doi: 10.1016/S0140-6736(22)02347.
    PubMed    
    
    
    
22. GUTTMAN-YASSKY E, Simpson EL, Reich K, Kabashima K, et al
    An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.
    Lancet. 2022 Dec 9:S0140-6736(22)02037-2. doi: 10.1016/S0140-6736(22)02037.
    PubMed     Abstract available
    
    
    September 2022
23. PALLER AS, Simpson EL, Siegfried EC, Cork MJ, et al
    Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2022;400:908-919.
    PubMed     Abstract available
    
    
    
24. HALLING AS, Thyssen JP
    Biological therapy for young children with atopic dermatitis.
    Lancet. 2022;400:867-869.
    PubMed    
    
    
    August 2022
25. DESCAMPS V
    DRESS syndrome.
    Lancet. 2022;400:560.
    PubMed    
    
    
    
26. JACKSON DJ, Bacharier LB, Gergen PJ, Gagalis L, et al
    Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.
    Lancet. 2022;400:502-511.
    PubMed     Abstract available
    
    
    
27. KELLY RS, Weiss ST
    Biologic therapies for asthma in underserved populations.
    Lancet. 2022;400:471-473.
    PubMed    
    
    
    July 2022
28. REICH K, Thyssen JP, Blauvelt A, Eyerich K, et al
    Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
    Lancet. 2022;400:273-282.
    PubMed     Abstract available
    
    
    
29. MENNINI M, Di Nardo G, Fiocchi AG
    Atopic dermatitis: time for tailored therapy.
    Lancet. 2022;400:252-253.
    PubMed    
    
    
    June 2022
30. SKJERVEN HO, Lie A, Vettukattil R, Rehbinder EM, et al
    Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial.
    Lancet. 2022;399:2398-2411.
    PubMed     Abstract available
    
    
    
31. PERKIN MR
    Early introduction of allergenic food for all infants.
    Lancet. 2022;399:2329-2331.
    PubMed    
    
    
    May 2022
32. ABDELNABI M, Elmssary M, Sekhon J, Benjanuwattra J, et al
    Acute onset of fever, eosinophilia, rash, acute kidney injury, and a positive Monospot test in a patient on lamotrigine: DRESS syndrome.
    Lancet. 2022;399:1902.
    PubMed    
    
    
    April 2022
33. LOMMATZSCH M, Brusselle GG, Canonica GW, Jackson DJ, et al
    Disease-modifying anti-asthmatic drugs.
    Lancet. 2022;399:1664-1668.
    PubMed    
    
    
    March 2022
34. CRAIG T, Magerl M, Levy DS, Reshef A, et al
    Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2022;399:945-955.
    PubMed     Abstract available
    
    
    
35. FIJEN LM, Levi M
    Prophylaxis with anti-activated factor XII for hereditary angioedema.
    Lancet. 2022;399:889-890.
    PubMed    
    
    
    January 2022
36. JONES SM, Kim EH, Nadeau KC, Nowak-Wegrzyn A, et al
    Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
    Lancet. 2022;399:359-371.
    PubMed     Abstract available
    
    
    
37. GREENHAWT M, Shaker M, Abrams EM
    Peanut oral immunotherapy in very young children.
    Lancet. 2022;399:336-337.
    PubMed    
    
    
    October 2021
38. ASHER MI, Rutter CE, Bissell K, Chiang CY, et al
    Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study.
    Lancet. 2021;398:1569-1580.
    PubMed     Abstract available
    
    
    
39. PIJNENBURG MW, Nantanda R
    Rising and falling prevalence of asthma symptoms.
    Lancet. 2021;398:1542-1543.
    PubMed    
    
    
    
40. JANKAUSKAITE L, Oostenbrink R
    Childhood lower respiratory tract infections: more evidence to do less.
    Lancet. 2021;398:1383-1384.
    PubMed    
    
    
    
41. BUSH A, Pavord ID
    Forthcoming UK asthma guidelines: an opportunity to improve asthma outcomes.
    Lancet. 2021 Oct 14. pii: S0140-6736(21)02244.
    PubMed    
    
    
    August 2021
42. SOAR J, Becker LB, Berg KM, Einav S, et al
    Cardiopulmonary resuscitation in special circumstances.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01257.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hypersensitivity Reaction is free of charge.